Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Astri Therapeutics Inc
(NQ:
ATXS
)
9.470
+0.460 (+5.11%)
Official Closing Price
Updated: 4:15 PM EDT, May 31, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Astri Therapeutics Inc
< Previous
1
2
3
Next >
Astria Therapeutics to Host Virtual R&D Day: Update on STAR-0215 and Its Clinical Development
September 16, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Investment Conferences
September 06, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 02, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
August 09, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
August 04, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Wedbush PacGrow Healthcare Conference 2022
August 03, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 02, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema
July 28, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Names Chris Morabito Chief Medical Officer
July 15, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Participate in Virtual Fireside Chat at Upcoming H.C. Wainwright 1st Annual Hereditary Angioedema Conference
July 14, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Presents New Preclinical Data Showing Differentiated Profile of STAR-0215, in Development for Treatment of Hereditary Angioedema
July 05, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present New Preclinical STAR-0215 Data at the European Academy of Allergy and Clinical Immunology 2022 Hybrid Congress
June 23, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Jefferies Healthcare Conference
June 03, 2022
From
Astria Therapeutics
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 02, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 12, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present STAR-0215 Data at the 2022 Fc Receptor and IgG Targeted Therapies Conference
April 21, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present STAR-0215 Data at the 2022 American Academy of Allergy, Asthma and Immunology Annual Meeting
February 18, 2022
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update
November 10, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
November 09, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Presents New Preclinical Data Showing the Differentiated Profile of STAR-0215, in Development to Treat Hereditary Angioedema
November 05, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Report Third Quarter 2021 Financial Results and Recent Corporate Developments on Wednesday, November 10
October 27, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present New STAR-0215 Preclinical Results at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting
October 21, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics Presents Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
October 18, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present Findings on Burdens of Disease and Treatment in Hereditary Angioedema at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit
October 12, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
Astria Therapeutics to Present at Upcoming Investor Conferences
September 10, 2021
From
Astria Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.